why choose us

Clinical Trials Search

Showing 19,220 of 132,963 result(s)
TACTIVE-U: A Study to Learn About the Study Medicine (Called ARV-471) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)

Status: Completed

Condition: Breast Cancer

Interventions: Daily oral dosages of ARV-471 continuously, dose escalation;de-escalation in Phase 1b until RP2D determined, cycles lasting 28 days

Date: 2022-10-05

Pilot Study to Evaluate Utility of EnteroTracker® as a Minimally Invasive Sampling Method to Screen for Barrett's Esophagus and Esophageal Cancer

Status: NOT_YET_RECRUITING

Condition: Barrett Esophagus

Interventions: The EnteroTracker® is a capsule device that includes an absorbent string.

Date: 2022-10-05

Cannabidiol as a Treatment for Social Anxiety Disorder (R61)

Status: Completed

Condition: Social Anxiety Disorder

Interventions: Oral Capsule Formulation of CBD dissolved in a self-emulsifying drug technology called nanodomains, encapsulated within 1-ml softgel capsules, with a

Date: 2022-10-05

A Open-label Study to Assess the Long-term Safety of Difamilast Ointment 1% in Mild to Moderate Atopic Dermatitis

Status: COMPLETED

Condition: Atopic Dermatitis

Interventions: Difamilast Ointment 1%

Date: 2022-10-05

Orthopaedic Treatment in Propulsive Metatarsalgia

Status: Completed

Condition: Metatarsalgia
Treatment
Foot
Foot Diseases
Orthopedic Disorder
Subluxation

Interventions: Interventional

Date: 2022-10-05

Benzodiazepine Taper With Cognitive Behavioral Therapy in Patients Using Prescription Opioids

Status: Completed

Condition: Anxiety Disorders

Interventions: 11 sessions of individual therapy consisting of exposure-based cognitive behavioral therapy that is designed specifically for assisting with benzodiaz

Date: 2022-10-05

A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

Status: Completed

Condition: Relapsed or Refractory Multiple Myeloma

Interventions: Teclistamab will be administered subcutaneously.

Date: 2022-10-05

Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Status: Completed

Condition: Advanced Solid Tumors

Interventions:

The dose levels to be evaluated in Part 1 are:

Cohort 1 600 mg (morning dose: 200 mg + evening dose: 400 mg); Cohort 2 800 mg (morning dose:

Date: 2022-10-05

Effect of MiniGo as add-on to Oral Laxatives for Children With Constipation and Fecal Incontinence

Status: Completed

Condition: Functional Constipation

Interventions: To be taken orally on a daily basis throughout the study period (6 weeks) in an adjusted dose.

Date: 2022-10-05